OR WAIT null SECS
© 2022 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Check out rheumatology's most groundbreaking FDA approvals of 2021!
The US FDA approved upadacitinib (15 mg daily) for the treatment of adults with active psoriatic arthritis with inadequate response to at least 1 TNF blocker.
Click the image to view the story.
The move comes amid delays in FDA approvals for multiple JAK inhibitors for the treatment of rheumatic conditions.
Click the image to view the story.
The US Food and Drug Administration (FDA) announced it has authorized a third dose of either the Pfizer/BioNTech or Moderna mRNA COVID-19 vaccines for patients with compromised immune systems, such as patients with rheumatic disease.
Click the image to view the story.